Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ad.2022.08.034 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic role of Androgen Receptor splice variant 7 (AR-V7) in the pathogenesis of breast cancer.
BMC Cancer
November 2024
Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.
Background: The Androgen Receptor (AR) has emerged as an endocrine therapy target in Breast Cancer, exhibiting up to 80% expression in clinical cases. AR-V7, a constitutively activated splice variant of AR with a truncated ligand-binding domain (LBD), demonstrates ligand-independent transcriptional activity and resistance to nonsteroidal antiandrogens like Bicalutamide or Enzalutamide, targeting the LBD. In metastatic prostate cancer, elevated AR-V7 levels lead to therapeutic resistance and increased metastasis.
View Article and Find Full Text PDFTowards sustainable water reuse: A critical review and meta-analysis of emerging chemical contaminants with risk-based evaluation, health hazard prediction and prioritization for assessment of effluent water quality.
J Hazard Mater
December 2024
Department of Aquatic Sciences and Assessment, Swedish University of Agricultural Sciences (SLU), SE-75007 Uppsala, Sweden. Electronic address:
Article Synopsis
- * There is insufficient knowledge on which CECs to monitor and how to evaluate their environmental impact, highlighting the need for improved understanding to inform regulations and guidelines for wastewater reuse.
- * This review identifies specific CECs hindering wastewater reuse and introduces a comprehensive methodology to assess and prioritize them based on their ecological and health hazards, revealing that several pharmaceuticals pose significant risks.
Real-world prevalence of adverse events with first-line systemic therapies among patients with metastatic castration-sensitive prostate cancer.
Prostate
November 2024
Astellas Pharma Inc., Northbrook, Illinois, USA.
Article Synopsis
- The study investigates the real-world occurrence of adverse events (AEs) in patients with metastatic castration-sensitive prostate cancer (mCSPC) receiving various treatments, reflecting a gap between current recommendations and actual practice.
- Data was collected from a large claims review in the U.S. between January 2014 and June 2021, focusing on 10 common AEs that significantly affect patient outcomes.
- A total of 4,145 patients were analyzed, with different treatment groups including ADT alone, ADT with nonsteroidal anti-androgens, docetaxel, and androgen receptor pathway inhibitors, enabling a comparison of AEs across these groups.
Epitranscriptomic mechanisms of androgen signalling and prostate cancer.
Neoplasia
October 2024
Biodiscovery Institute, University of Nottingham, UK; School of Veterinary Medicine and Science, University of Nottingham, UK. Electronic address:
Prostate cancer (PCa) is the second most common cancer diagnosed in men. While radical prostatectomy and radiotherapy are often successful in treating localised disease, post-treatment recurrence is common. As the androgen receptor (AR) and androgen hormones play an essential role in prostate carcinogenesis and progression, androgen deprivation therapy (ADT) is often used to deprive PCa cells of the pro-proliferative effect of androgens.
View Article and Find Full Text PDFThree- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide.
Eur Urol Oncol
October 2024
University of Utah, Salt Lake City, UT, USA.
Article Synopsis
- The study investigates how changes in prostate-specific antigen (PSA) levels at 3 and 7 months of androgen deprivation therapy (ADT) relate to overall survival in patients with metastatic hormone-sensitive prostate cancer (mHSPC).
- Results show that a complete response (CR) in PSA at both 3 and 7 months significantly correlates with improved overall survival compared to no response, with specific statistical measures supporting this association.
- The findings suggest that monitoring PSA levels can help identify patients at higher risk of death, aiding in treatment decisions and the design of future clinical trials.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!